
June 17 (Reuters) - Foresee Pharmaceuticals Co Ltd 6576.TWO:
FORESEE PHARMACEUTICALS ANNOUNCES REACHING A SIGNIFICANT MILESTONE, OF COMPLETE ENROLLMENT OF ITS PHASE 3 CASPPIAN TRIAL FOR PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY (CPP)
FORESEE PHARMACEUTICALS CO LTD - TOPLINE RESULTS FROM PHASE 3 CASPPIAN TRIAL EXPECTED BY END OF 2025
FORESEE PHARMACEUTICALS CO LTD - PLANS NDA SUBMISSION BY Q3 2026 BASED ON STUDY OUTCOMES